Cost-effectiveness for metastatic colorectal cancer.

被引：1
|
作者：
Yao, Linli
Han, Jiaqi
She, Longjiang
Ding, Dong
Liao, Mengting
Hu, Huabin
Zeng, Shan
Shen, Liangfang
Huang, Jin
机构：
[1] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer.
    Barzi, Afsaneh
    Cho, Sang K.
    Hay, Joel W.
    Lenz, Heinz-Josef
    Ou, Fang-Shu
    Grothey, Axel
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Cost-effectiveness of aspirin chemoprophylaxis for colorectal cancer.
    Ladabaum, U
    Chopra, CL
    Huang, G
    Chernew, ME
    Scheiman, JM
    Fendrick, AM
    GASTROENTEROLOGY, 1999, 116 (04) : A447 - A447
  • [4] Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.
    Tam, V. C.
    Ko, Y.
    Mittmann, N.
    Kumar, K.
    Hassan, S.
    Cheung, M. C.
    Chan, K. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer.
    Degeling, Koen
    Vu, Martin
    Koffijberg, Hendrik
    Wong, Hui-Li
    Koopman, Miriam
    Gibbs, Peter
    IJzerman, Maarten J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3727 - +
  • [8] Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer.
    Lange, Joel
    Rajeev, Rahul
    Gamblin, T. Clark
    Turaga, Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [9] Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
    Kang, Dong-Won
    Lynn, Patricio B.
    Wang, Li
    Zhou, Shouhao
    Shen, Chan
    PHARMACOECONOMICS-OPEN, 2024, : 93 - 101
  • [10] Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
    Sherman, Scott K.
    Lange, Joel J.
    Dahdaleh, Fadi S.
    Rajeev, Rahul
    Gamblin, T. Clark
    Polite, Blase N.
    Turaga, Kiran K.
    JAMA ONCOLOGY, 2019, 5 (02) : 236 - 242
12345